EE200300052A - Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid - Google Patents

Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid

Info

Publication number
EE200300052A
EE200300052A EEP200300052A EEP200300052A EE200300052A EE 200300052 A EE200300052 A EE 200300052A EE P200300052 A EEP200300052 A EE P200300052A EE P200300052 A EEP200300052 A EE P200300052A EE 200300052 A EE200300052 A EE 200300052A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
transfer protein
cholesteryl ester
protein inhibitors
ester transfer
Prior art date
Application number
EEP200300052A
Other languages
English (en)
Inventor
John Curatolo William
Thomas Friesen Dwayne
Jon Gumkowski Michael
Alan Lorenz Douglas
Alan Schriver Nightingale James
Benjamin Ruggeri Roger
Mysore Shanker Ravi
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22835821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300052A publication Critical patent/EE200300052A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EEP200300052A 2000-08-03 2001-07-31 Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid EE200300052A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22327900P 2000-08-03 2000-08-03
PCT/IB2001/001391 WO2002011710A2 (en) 2000-08-03 2001-07-31 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number Publication Date
EE200300052A true EE200300052A (et) 2004-12-15

Family

ID=22835821

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300052A EE200300052A (et) 2000-08-03 2001-07-31 Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid

Country Status (40)

Country Link
US (4) US7115279B2 (et)
EP (2) EP2258352B1 (et)
JP (2) JP2004505911A (et)
KR (1) KR100561572B1 (et)
CN (1) CN1458840A (et)
AP (1) AP2001002235A0 (et)
AR (1) AR030570A1 (et)
AT (1) ATE503462T1 (et)
AU (1) AU2914202A (et)
BG (1) BG107456A (et)
BR (1) BR0112828A (et)
CA (1) CA2417755A1 (et)
CR (1) CR6883A (et)
CZ (1) CZ2003224A3 (et)
DE (1) DE60144332D1 (et)
DO (1) DOP2001000224A (et)
DZ (1) DZ3391A1 (et)
EA (1) EA007013B1 (et)
EC (1) ECSP034462A (et)
EE (1) EE200300052A (et)
GT (1) GT200100156A (et)
HN (1) HN2001000175A (et)
HU (1) HUP0300676A2 (et)
IL (1) IL154017A0 (et)
IS (1) IS6688A (et)
MA (1) MA26935A1 (et)
MX (1) MXPA03001035A (et)
NO (1) NO20030506D0 (et)
NZ (1) NZ523680A (et)
OA (1) OA12350A (et)
PA (1) PA8523901A1 (et)
PE (1) PE20020271A1 (et)
PL (1) PL365168A1 (et)
PY (1) PY0119147A (et)
SK (1) SK1032003A3 (et)
SV (1) SV2002000581A (et)
TN (1) TNSN01119A1 (et)
UY (1) UY26864A1 (et)
WO (1) WO2002011710A2 (et)
ZA (1) ZA200300869B (et)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
CA2450762A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1469830A2 (en) * 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CN1688291A (zh) 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
CN1681479A (zh) * 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
ZA200508160B (en) * 2003-03-17 2007-01-31 Japan Tobacco Inc Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
ES2320770T3 (es) * 2004-05-26 2009-05-28 Arturo Jimenez Bayardo Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida.
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US20080145427A1 (en) * 2005-02-03 2008-06-19 Alfred Berchielli Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CN101378731B (zh) * 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1997819A1 (de) 2007-05-25 2008-12-03 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Scopinestern
US8337835B2 (en) * 2009-04-10 2012-12-25 Washington University Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (et) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
AU2013346501B2 (en) * 2012-11-19 2017-07-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299641B1 (en) 1987-07-17 1992-06-10 Dow Corning Corporation A curable composition
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5093371A (en) * 1990-07-02 1992-03-03 University Of Iowa Research Foundation Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5446207A (en) * 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
EP0733061A1 (en) 1994-11-12 1996-09-25 LG Chemical Limited Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
GB2305665A (en) 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
JP3290962B2 (ja) * 1997-02-12 2002-06-10 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
DE69824901D1 (de) * 1997-04-16 2004-08-05 Univ New Mexico Albuquerque Cholesterin Esterase Inhibitoren
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JP3433417B2 (ja) * 1998-04-02 2003-08-04 トヨタ自動車株式会社 レーダ装置
ATE349203T1 (de) * 1998-06-11 2007-01-15 Pharmacia & Upjohn Co Llc Delavirdin tablettenformulierung
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CA2345108A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
JP3924124B2 (ja) 1998-09-25 2007-06-06 ファルマシア・コーポレーション コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU751849B2 (en) 1999-03-08 2002-08-29 Kitasato Institute, The Substances WK-5344A and WK-5344B and process for producing the same
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
DK1242055T3 (da) * 1999-12-23 2008-07-21 Pfizer Prod Inc Hydrogelstyret doseringsform til lægemidler
AU2001233299A1 (en) 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CA2450762A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.

Also Published As

Publication number Publication date
HUP0300676A2 (hu) 2003-08-28
ZA200300869B (en) 2004-04-16
EP2258352A2 (en) 2010-12-08
CA2417755A1 (en) 2002-02-14
WO2002011710A3 (en) 2002-05-02
DE60144332D1 (de) 2011-05-12
NO20030506L (no) 2003-01-31
CR6883A (es) 2003-11-25
AP2001002235A0 (en) 2001-09-30
EP1305007A2 (en) 2003-05-02
EA200300073A1 (ru) 2003-08-28
UY26864A1 (es) 2002-02-28
PA8523901A1 (es) 2002-04-25
BG107456A (bg) 2003-09-30
KR20030026995A (ko) 2003-04-03
PY0119147A (es) 2003-11-03
CZ2003224A3 (cs) 2004-02-18
IL154017A0 (en) 2003-07-31
ATE503462T1 (de) 2011-04-15
NZ523680A (en) 2004-09-24
PE20020271A1 (es) 2002-04-08
US8048452B2 (en) 2011-11-01
US20120277315A1 (en) 2012-11-01
US7115279B2 (en) 2006-10-03
US8197848B2 (en) 2012-06-12
NO20030506D0 (no) 2003-01-31
AU2914202A (en) 2002-02-18
US8389011B2 (en) 2013-03-05
EP2258352A3 (en) 2013-08-14
EP2258352B1 (en) 2015-05-13
MXPA03001035A (es) 2003-05-27
CN1458840A (zh) 2003-11-26
GT200100156A (es) 2002-04-23
US20060211654A1 (en) 2006-09-21
ECSP034462A (es) 2003-03-31
JP2004505911A (ja) 2004-02-26
WO2002011710A2 (en) 2002-02-14
JP2007314573A (ja) 2007-12-06
US20020103225A1 (en) 2002-08-01
MA26935A1 (fr) 2004-12-20
TNSN01119A1 (fr) 2005-11-10
OA12350A (en) 2006-05-16
PL365168A1 (en) 2004-12-27
AR030570A1 (es) 2003-08-27
EP1305007B1 (en) 2011-03-30
EA007013B1 (ru) 2006-06-30
DOP2001000224A (es) 2002-06-15
SK1032003A3 (en) 2004-05-04
HN2001000175A (es) 2001-10-08
KR100561572B1 (ko) 2006-03-16
IS6688A (is) 2003-01-16
BR0112828A (pt) 2003-07-01
DZ3391A1 (fr) 2002-02-14
US20070282009A1 (en) 2007-12-06
SV2002000581A (es) 2002-10-24

Similar Documents

Publication Publication Date Title
NO20030506D0 (no) Farmasöytiske sammensetninger av kolesterylesteroverföringsproteininhibitorer
EE200400024A (et) Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
NO20043506L (no) Kontrollert frigivende farmasoytiske doseringsformer av en kolesterylester overforingsproteininhibitor
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
EE200200393A (et) Glüburiidi ravimkoostis
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
FI20105657L (fi) Farmaseuttisia koostumuksia
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
EP1315500A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION OF CYCLOOXYGENASE-2 INHIBITORS
PT1242087E (pt) Composicoes farmaceuticas
NO20014893D0 (no) Farmasöytiske sammensetninger av erythropoietin
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
NO20031095L (no) Farmasoytiske sammensetninger
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
EE200100084A (et) NOS inhibiitorite uued farmatseutilised kasutusvoimalused
EE200200429A (et) Kolesteroolestri ja vahaestri sünteesi duaalsed inhibiitorid rasunäärme häirete jaoks
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
EE200200689A (et) Ravimkoostised
SE0000934D0 (sv) Method of preparing pharmaceutical compositions
IDP000026456A (id) Senyawa-senyawa siklopropanakarboksilat ester
ITMI20000360A0 (it) Gel orale contenente composti aminoacidi solforati
SE0001743D0 (sv) Stable protein compositions II